Skip to content
lifestyle.californiaconsumerbanking.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Cerenome, Inc.
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
November 13, 2026
Cerenome to Review REYOBIQ ReSPECT-LM Data Presented at SNO Conference and Provide CNSide Commercial Update on November 16
November 12, 2026
Cerenome Appoints Director Ron Andrews as Chief Business Officer
November 10, 2026
Cerenome Secures National In-Network Agreement with Aetna for CNSide®
November 4, 2026
Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
October 29, 2026
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
October 27, 2026
Cerenome Announces New Dual Mechanism of Action Featuring Lethal DNA Damage and Beneficial Immunomodulation Supporting Lead Investigational Drug REYOBIQ™
October 21, 2026
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
October 8, 2026
Cerenome Launches CNSide® CSF Molecular Profile Tests
October 6, 2026
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
September 30, 2026
1
2
Next Page
→